Johnson & Johnson (JNJ) Stock Price, Quote & News

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospit...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 732 524 0400

Website: www.jnj.com

Address:

One Johnson & Johnson Plaza, New Brunswick, United States

77HighStreet Aug. 17 at 8:09 PM

$JNJ Sold my JNJ today...I know, I am selling too early. But I have been in it for over 4 years and am more than grateful for my profit...besides, junior is entering his senior year at Auburn and I want to make sure I can pay the final tuition. Besides, if I sell, that is probably good luck for you guys. GLTA!

0 · Reply

SellasgpsCurativeBAT11 Aug. 17 at 4:03 PM

$JNJ $SLS Why Sellas will be one of the biggest BO of this decade? Sellas GPS Ad Infinitum Dosage + SLS009 Dual Platform offers end to end solutions to eradicate most dangerous cancers on the planet from start to finish= $200.00++ ✌️🙏❤️‍🩹

0 · Reply

BioBroke Aug. 17 at 4:01 PM

$SLS Let $JNJ announce the 80th event whenever that may happen.😉

0 · Reply

SellasgpsCurativeBAT11 Aug. 17 at 3:55 PM

$SLS $JNJ Johnson & Johnson announced on August 4, 2026, that Executive Vice President and Worldwide Chairman of Innovative Medicine Jennifer Taubert will retire, effective September 1, 2026. Tom Cavanaugh, currently Company Group Chairman for North America in the division, will succeed her. Mr. Cavanaugh and Sellas BOD Katherine Bach principals involved in biggest Pharmaceutical deal of all time. Bristol-Myers Squibb completed its $74 billion acquisition of Celgene Corporation on November 20, 2019. The cash-and-stock deal created a premier global biopharmaceutical giant focused on oncology, immunology, and cardiovascular disease. ✌️🙏❤️‍🩹

1 · Reply

Imr77 Aug. 17 at 3:50 PM

$SLS $JNJ same guy, shouting out to SLS and MSK (where they developed GPS first!)

0 · Reply

SellasgpsCurativeBAT11 Aug. 17 at 3:46 PM

$SLS $JNJ Part 3. Very interesting that $JNJ Michael Frascello, MBA • 3rd+ Product Director @ Johnson & Johnson | MBA, Marketing. Is always very first ones to like Dr. Stergiou posts every time. Probably a coincidence. 😆 ✌️🙏❤️‍🩹

0 · Reply

JuggernautRaider Aug. 17 at 10:56 AM

$PHAR needs a lot of help. Big Wim at Pharvarid $PHVS is about to eat their HAE lunch like Kalvista did before they got bounced. Pharming Group of NJ? It is a mess! I may help them. I may not. I have a couple of friends there… maybe if they ask niiiicely 😜 Maybe $AXSM should buy something like Tonix after all. NJ is a MESS! GO $JNJ GO! FIX AMERICAAAAAAAN HEALTHCARE 🇺🇸 🧪 🤖

0 · Reply

JFais Aug. 16 at 9:23 PM

$XNCR - $JNJ bought $12M worth of shares in Q2 Likely a nothing-burger, but a logical suitor for sure 🤔 (hat tip to Mike in Chat)

0 · Reply

BioTechHealthX Aug. 15 at 5:24 PM

$JNJ Johnson & Johnson (NYSE: JNJ) is reshaping its healthcare empire around pharmaceuticals and MedTech. Here’s why analysts see potential upside for JNJ stock in 2026. https://biotechhealthx.com/biotech-news/is-johnson-johnson-jnj-still-a-good-choice-for-long-term-investors/

0 · Reply

TalkMarkets Aug. 15 at 7:35 AM

This Dividend Aristocrat Posted Record Quarterly Results $JNJ https://talkmarkets.com/article/this-dividend-aristocrat-posted-record-quarterly-results-1786779294

0 · Reply

Oppenheimer upgrades Intuitive Surgical on lack of U.S. competition

ISRG

Aug 13, 2026, 11:15 PM EDT - 3 days ago

Expert explains why healthcare is a top-performing sector

ABBV AMGN BIIB GILD LLY MRK UNH

Aug 10, 2026, 4:27 PM EDT - 6 days ago

Johnson & Johnson to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

2026-08-07T19:33:43.000Z - 10 days ago

3 ‘Strong Buy’ Dividend Aristocrat Stocks to Grab Right Now to Get Paid in September — 8/7/26

CVX WMT

Aug 6, 2026, 6:23 PM EDT - 10 days ago

Jim Cramer highlights 5 investing themes — and the stocks to buy for each

AMAT AXP COF CRWD GS KLAC LLY

2026-08-06T10:48:29.000Z - 11 days ago

Johnson & Johnson price target raised to $287 from $270 at Guggenheim

2026-08-05T18:48:12.000Z - 12 days ago

3 ‘Strong Buy’ Dividend Aristocrat Stocks for Dependable Income, 8/5/26

IBM KO

Aug 4, 2026, 4:05 PM EDT - 13 days ago

Johnson & Johnson to Participate in the 2026 Wells Fargo Healthcare Conference

2026-08-04T12:50:51.000Z - 13 days ago

Johnson & Johnson announces Taubert to retire as EVP, Worldwide Chairman

Aug 4, 2026, 8:45 AM EDT - 13 days ago

Johnson & Johnson's Executive Vice President Jennifer Taubert to Retire; Tom Cavanaugh Appointed EVP, Worldwide Chairman Innovative Medicine Effective September

Aug 3, 2026, 8:00 AM EDT - 14 days ago

Johnson & Johnson Transcript: Investor update

2026-08-03T11:00:29.000Z - 14 days ago

Johnson & Johnson price target raised to $282 from $272 at Wells Fargo

2026-08-03T09:35:43.000Z - 14 days ago

Johnson & Johnson removed from US Conviction List at Goldman Sachs

Aug 2, 2026, 8:00 AM EDT - 15 days ago

Inside J&J's Lab to Create a Simpler Robotic Surgery Device

2026-07-30T12:35:46.000Z - 18 days ago

Johnson & Johnson’s head & neck cancer candidate granted FDA Priority Review

Jul 30, 2026, 8:30 AM EDT - 18 days ago

Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer

Jul 29, 2026, 6:13 PM EDT - 18 days ago

Johnson & Johnson Comes to Strategic Agreement with Sail Biomedicines

Jul 29, 2026, 5:42 PM EDT - 18 days ago

Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation

Jul 29, 2026, 5:38 PM EDT - 18 days ago

Johnson & Johnson lowers 2026 profit forecast

Jul 29, 2026, 5:28 PM EDT - 18 days ago

Johnson & Johnson Announces Collaboration with Sail Biomedicines to Advance in vivo CAR-T Programs and Transform Autoimmune Disease Through Immune Reset

Jul 29, 2026, 12:01 PM EDT - 19 days ago

Explainer: Can J&J finally put the talc litigation behind it?

Jul 28, 2026, 4:31 PM EDT - 19 days ago

Johnson & Johnson offers $5.5 billion to settle remaining lawsuits over talc products linked to cancer

Jul 28, 2026, 12:26 PM EDT - 20 days ago

Johnson & Johnson agrees to pay $5.5B to settle talc lawsuits

Jul 28, 2026, 1:03 AM EDT - 20 days ago

Johnson & Johnson to pay $5.5bn settlement in talc cancer lawsuit

Jul 28, 2026, 12:31 AM EDT - 20 days ago

J&J offers $5.5bn to settle baby powder lawsuits

Jul 27, 2026, 9:29 PM EDT - 20 days ago

Johnson & Johnson Agrees to Pay $5.5 Billion to Settle Talc Lawsuits

Jul 27, 2026, 6:47 PM EDT - 20 days ago

Johnson & Johnson announces $5.5 billion settlement of talc lawsuits

Jul 27, 2026, 6:31 PM EDT - 20 days ago

Johnson & Johnson Announces a Proposed Resolution of Ovarian Talc Litigation

Jul 27, 2026, 5:45 AM EDT - 21 days ago

Robert Kiyosaki sees a brutal depression ahead: 3 stocks that may protect portfolios

NEM WMT

$TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma$

Jul 23, 2026, 8:30 AM EDT - 25 days ago

TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma

Jul 22, 2026, 4:33 PM EDT - 25 days ago

US judge casts doubt on 69,000 cases alleging J&J talc caused cancer

Jul 22, 2026, 7:21 AM EDT - 26 days ago

Johnson & Johnson's robotic surgery device gets US FDA marketing authorization

Jul 22, 2026, 7:00 AM EDT - 26 days ago

Johnson & Johnson Receives FDA Market Authorization in the U.S. for its OTTAVA™ Robotic Surgical System

Jul 21, 2026, 6:30 PM EDT - 26 days ago

Jim Cramer says this old-school investing concept still wins — even in the AI boom

BNY CVS GS MMM WFC

Jul 16, 2026, 8:11 AM EDT - 4 weeks ago

Johnson & Johnson Announces Collaboration with TIME to Introduce New Healthcare Champion of the Year Award

Jul 16, 2026, 8:00 AM EDT - 4 weeks ago

DePuy Synthes Acquires Expanding Innovations™

Jul 15, 2026, 12:09 PM EDT - 4 weeks ago

J&J Leverages AI and Robots to Target $100 Billion in Annual Revenue

Jul 15, 2026, 8:30 AM EDT - 4 weeks ago

Johnson & Johnson Earnings Call Transcript: Q2 2026

Jul 15, 2026, 8:30 AM EDT - 4 weeks ago

Johnson & Johnson Slides: Q2 2026

Jul 15, 2026, 8:30 AM EDT - 4 weeks ago

Johnson & Johnson Earnings release: Q2 2026

Jul 15, 2026, 8:30 AM EDT - 4 weeks ago

Johnson & Johnson Quarterly report: Q2 2026

Jul 15, 2026, 7:27 AM EDT - 4 weeks ago

ASML, Intel, Johnson & Johnson, and More Stocks That Explain Today's Market

ASML INTC

Jul 15, 2026, 6:35 AM EDT - 4 weeks ago

Johnson & Johnson Hikes Guidance, Stock Falls

Jul 15, 2026, 6:33 AM EDT - 4 weeks ago

Johnson & Johnson Bumps Up Guidance as Sales Rise

Jul 15, 2026, 6:25 AM EDT - 4 weeks ago

Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2026

Jul 15, 2026, 6:23 AM EDT - 4 weeks ago

J&J quarterly earnings beat Wall Street estimates on strength of medicines unit

Jul 15, 2026, 6:20 AM EDT - 4 weeks ago

Johnson & Johnson reports Q2 2026 results, raises 2026 outlook

Jul 9, 2026, 1:00 PM EDT - 5 weeks ago

The Big 3: UNH, KO, JNJ

KO UNH

Jul 8, 2026, 7:45 AM EDT - 5 weeks ago

Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform

Jul 6, 2026, 6:29 PM EDT - 5 weeks ago

Jim Cramer says these are the 5 stocks to buy during this market rotation

PEP SBUX STZ TJX

Jun 26, 2026, 2:39 PM EDT - 7 weeks ago

Healthcare stocks have become a haven for investors ditching tech

ABBV ABSI APGE LLY MRNA SNY XBI

Jun 26, 2026, 12:35 PM EDT - 7 weeks ago

Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis

Jun 25, 2026, 5:00 AM EDT - 7 weeks ago

Johnson & Johnson Advances Cardiac Ablation Technology in Europe with Availability of Dual Energy THERMOCOOL SMARTTOUCH SF Platform

Jun 15, 2026, 6:00 AM EDT - 2 months ago

Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida

$New TALVEY®▼(talquetamab) plus daratumumab data demonstrate the potential strength of a novel bispecific combination in earlier-line relapsed or refractory multiple myeloma$

Jun 13, 2026, 6:41 AM EDT - 2 months ago

New TALVEY®▼(talquetamab) plus daratumumab data demonstrate the potential strength of a novel bispecific combination in earlier-line relapsed or refractory multiple myeloma

$New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma$

Jun 13, 2026, 6:33 AM EDT - 2 months ago

New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma

Jun 11, 2026, 7:45 AM EDT - 2 months ago

Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients

Jun 11, 2026, 2:03 AM EDT - 2 months ago

IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies

Jun 10, 2026, 11:22 AM EDT - 2 months ago

Johnson & Johnson Hit with $32 Million Verdict in Los Angeles Asbestos Trial

Jun 10, 2026, 6:20 AM EDT - 2 months ago

Johnson & Johnson CEO Says Cure for Certain Cancers Is Realistic Goal

Jun 9, 2026, 10:00 AM EDT - 2 months ago

Johnson & Johnson Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 9, 2026, 9:20 AM EDT - 2 months ago

Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying

AMGN LLY MRK NVO PFE

Jun 8, 2026, 9:01 AM EDT - 2 months ago

Johnson & Johnson to Buy Firefly Bio for $1 Billion

77HighStreet Aug. 17 at 8:09 PM

0 · Reply

SellasgpsCurativeBAT11 Aug. 17 at 4:03 PM

0 · Reply

BioBroke Aug. 17 at 4:01 PM

$SLS Let $JNJ announce the 80th event whenever that may happen.😉

0 · Reply

SellasgpsCurativeBAT11 Aug. 17 at 3:55 PM

1 · Reply

Imr77 Aug. 17 at 3:50 PM

$SLS $JNJ same guy, shouting out to SLS and MSK (where they developed GPS first!)

0 · Reply

SellasgpsCurativeBAT11 Aug. 17 at 3:46 PM

0 · Reply

JuggernautRaider Aug. 17 at 10:56 AM

0 · Reply

JFais Aug. 16 at 9:23 PM

$XNCR - $JNJ bought $12M worth of shares in Q2 Likely a nothing-burger, but a logical suitor for sure 🤔 (hat tip to Mike in Chat)

0 · Reply

BioTechHealthX Aug. 15 at 5:24 PM

0 · Reply

TalkMarkets Aug. 15 at 7:35 AM

This Dividend Aristocrat Posted Record Quarterly Results $JNJ https://talkmarkets.com/article/this-dividend-aristocrat-posted-record-quarterly-results-1786779294

0 · Reply

BarkingPuppy Aug. 14 at 7:05 PM

$ELTP $DJT $GME $PFE $JNJ The Rumors in the Bio-tech world are going crazy. Who is going to Grab ELTP in America Before a Foreign Company Buys them???? I would like to keep it in American Hands, I think their ART technology is far to great and powerful to let a none US company acquire this There is no official corporate announcement or confirmed agreement that Elite Pharmaceuticals (ELTP) is being bought by a foreign buyer. Online retail investor communitie have heavily speculated about a potential company buyout—including theories involving international or foreign acquirers motivated by manufacturing capacities or tariff strategies. However, these claims remain unverified market speculation and rumor rather than official business operations. The company's management has previously discussed a sale or buyout as a strategic option to maximize shareholder value or address listing requirements, but no foreign acquisition deal has been finalized or announced.

0 · Reply

GoforProMIS Aug. 14 at 5:20 PM

$PMN Guggenheim raised PT to $100 Skipping Phase 2: Question of dosage has been resolved. If a 1b trial as PMN310 tests various escalating dose groups 5 mg to max. dose of 20 mg on actual patients, it has already accomplished the primary objective of Phase 2. Exceptional regarding biomarkers: When evidence is mathematically irrefutable—rendering it logically impossible to question the drugs efficacy— FDA no longer requires an artificial interim study. Impeccable safety at the maximum dose, if the DSMB records a 0.0% incidence of severe side effects at the max. dose during the Phase 1b trial, the primary regulatory hurdle is removed. High unmet medical need: FDA accelerates the process for fatal or incurable diseases like Alzheimer’s. If PMN shows the potential to be safer than existing treatments as Lilly Biogen . FDA views it ethical imperative to expedite the approval process through fast-track programs. $PFE $JNJ $BMY

0 · Reply

TraderDaKing Aug. 14 at 3:28 PM

$JNJ $PFE $LLY $MRNA I know you are listening and buying after the new during the call. Elite Pharma. Welcome to the Big Times.

0 · Reply

CoronaSecurities Aug. 14 at 3:06 PM

$BETR $BABA $CRVS $JNJ BETR remains highly speculative, Alibaba benefits from Chinese commerce and cloud demand, CervoMed advances neurological treatments, and Johnson & Johnson provides diversified healthcare exposure. I'm watching liquidity, Chinese consumption, clinical milestones, and healthcare demand.

0 · Reply

chop14 Aug. 14 at 2:15 PM

$ARTL still nice but still low volume ! $JNJ $PFE $SLDB $LLY

0 · Reply

HydrogenH2 Aug. 14 at 2:09 PM

$JNJ I will add under $250 !! Here why... !!

0 · Reply

BarkingPuppy Aug. 14 at 1:59 PM

$ELTP $JNJ $DJT $GME Elite Pharmaceuticals (ELTP) delivered a solid earnings report yesterday, showcasing strong financial performance despite some revenue challenges. For the quarter ending June 30, 2026, ELTP reported revenue of $32.4 million and a net income of $5.9 million, reflecting effective operational management and robust cash flow. This positive outcome highlights the company's resilience and strategic focus. A key highlight in ELTP's portfolio is SequestOx, an innovative product that continues to drive interest and confidence among investors. The success of SequestOx underscores ELTP's commitment to advancing pharmaceutical solutions with significant market potential. Overall, ELTP's earnings report from yesterday signals a promising outlook, reinforcing its position as a noteworthy player in the pharmaceutical sector. Investors can look forward to the continued impact of SequestOx and other developments as ELTP moves forward. The Conference call will be Great. 11:30

1 · Reply

ZacksResearch Aug. 14 at 1:10 PM

"3 large-cap pharma stocks to watch as recovery takes hold 👀 $LLY, $JNJ and $BAYRY stand out as the industry shows strong recovery, driven by innovation, positive regulatory updates and a major wave of M&A activity. 📈 LLY: Strong cardiometabolic momentum 💊 JNJ: Diversified portfolio + pipeline 🚀 BAYRY: Key drug growth + new launches See why these 3 pharma stocks are worth watching 👉 Latest LLY news here 👉 " https://www.zacks.com/stock/quote/LLY?q=lly&art_rec=quote-stock_overview-search_filter-zcom-LLY&cid=sm-stocktwits-0-quote_overview-oc-39254&ADID=SYND_STOCKTWITS_TWEET_0_QUOTEOVERVIEW_OC_39254

0 · Reply

DidYouReadThis Aug. 14 at 1:07 PM

$JNJ $SF $MS $BLK How’s your Friday going?

0 · Reply

TraderDaKing Aug. 14 at 12:04 PM

$JNJ $LLY $MRNA You guys doing something with Elite????

0 · Reply

DidYouReadThis Aug. 14 at 12:00 PM

$REGN $NVS $ABBV $JNJ Are you more:

0 · Reply

Quantumup Aug. 14 at 10:35 AM

Citizens reiterated $IMMX Market Outperform-$23 and said that it sees 273% pot'l⬆️for its bull case ($42) and 47% pot'l⬇️for its bear case ($6). $PRTA $JNJ - GMAB BMY GILD - ACLX AZN ABBV REGN Citizens said -- We reiterate our Market Outperform rating and price target of $23 for Immix Biopharma based on a revenue and earnings multiples analysis. Recently, Immix reported 2Q26 earnings, and based on our conversation with management, we remain confident in regard to the cadence of value-driving milestones over the next 6-12 months. With NXC-201 on track to report top-line results in September and file a BLA in 1H27, a potential commercial launch by year-end 2026/early 2027, and a solid cash position of $232.1MM, we believe Immix shares represent an attractive investment opportunity, with ~47% potential downside (bear case $6) and ~273% potential upside (bull case $42).

0 · Reply

Market Cap	627.42B
Revenue (ttm)	94.19B
Net Income (ttm)	26.80B
EPS (ttm)	N/A
PE Ratio	24.13
Forward PE	22.57
Profit Margin	28.46%
Debt to Equity Ratio	0.44

Volume	5,503,429
Avg Vol	8,198,646
Day's Range	N/A - N/A
Shares Out	2.41B
Stochastic %K	72%
Beta	0.24
Analysts	Strong Sell
Price Target	$275.42